Merck KGaA Hopes UK Cancer Charity R&D Pact Will Yield New Assets
Executive Summary
The multi-project collaboration and licensing deal between charities Cancer Research UK and Germany's Merck aims to discover and commercialize novel cancer treatment assets.
You may also be interested in...
Deal Watch: From The Sidelines Of J.P. Morgan, Lots Of Discovery Deals
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.